Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Capital Expenditures (2024 - 2025)

Xilio Therapeutics' Capital Expenditures history spans 2 years, with the latest figure at $131000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures rose 1191.67% year-over-year to $131000.0; the TTM value through Sep 2025 reached $429000.0, changed N/A, while the annual FY2024 figure was $36000.0, 92.59% down from the prior year.
  • Capital Expenditures for Q2 2025 was $131000.0 at Xilio Therapeutics, down from $292000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $292000.0 in Q1 2025 and bottomed at -$12000.0 in Q2 2024.